Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07410039 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study

Study acronym: ETA/PETA-NMOSD
StatusRecruiting
PhasePhase 4
Started2026-02-01
View on ClinicalTrials.gov ↗

Amendment history

2026-03-10
Not Yet Recruiting→Recruiting Study Status, Conditions, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2026-06-30→2027-06-30
Completion date2026-06-30→2029-06-30
Study sites0→1
2026-02-27
Study Identification, Study Status, Contacts/Locations v1
Study title-40 characters
Eculizumab Add-On Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study（ETA/PETA-NMOSD Study）
2026-02-07
Original filing
This project is a multi-center, prospective, real-world cohort study that collects clinical data of Chinese patients with AQP4-positive NMOSD in the acute stage. It comprehensively assesses the clinical outcomes of the patients and aims to compare the clinical efficacy and safety of icoxib as a combined add-on treatment versus simple hormone shock therapy during the acute phase of NMOSD.Using simple hormone shock therapy (IVMP) as the control group, the efficacy and safety of etanercept treatment in the acute attack phase of Chinese patients with AQP4-positive neuromyelitis optica spectrum disorder (NMOSD) were evaluated.
Trial Details
NCT Number NCT07410039
Lead Sponsor Chinese PLA General Hospital
Conditions Neuromyelitis Optica Spectrum Disorder Attack
Enrollment 200 participants
Start Date 2026-02-01
Primary Completion 2027-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-12